ROCHE
Updates & Highlights
ADA: Obesity partners Zealand and Roche aim for weight loss ‘sweet spot’ with amylin agonist
ADA: Obesity partners Zealand and Roche aim for weight loss ‘sweet spot’ with amylin agonist
BioSpace · 1 day ago
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial
Reuters · 1 day ago
Roche develops Bundibugyo Ebola test in six days
Roche develops Bundibugyo Ebola test in six days
pharmaphorum · 1 day ago
Recent Openings
View all 1 jobsCulture & Mission
Benefits & Perks
Equity/Stock Options
Ownership in the company
Health Insurance
Medical, dental & vision
Remote Work
Work from anywhere flexibility
Learning Budget
Professional development
Generous PTO
Paid time off
Parental Leave
Family-friendly policies
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Roche?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company →News & Press
20 recentADA: Obesity partners Zealand and Roche aim for weight loss ‘sweet spot’ with amylin agonist
ADA: Obesity partners Zealand and Roche aim for weight loss ‘sweet spot’ with amylin agonist
BioSpace · 1 day ago
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial
Reuters · 1 day ago
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial
Yahoo · 1 day ago
Roche develops Bundibugyo Ebola test in six days
Roche develops Bundibugyo Ebola test in six days
pharmaphorum · 1 day ago
Roche chair compares US tariff policy to ‘blackmail’
Roche chair compares US tariff policy to ‘blackmail’
SWI swissinfo.ch · 2 days ago
Roche chairman likens US tariff policy to 'blackmail'
Roche chairman likens US tariff policy to 'blackmail'
Reuters · 3 days ago
Rita Marie Roche
Rita Marie Roche
The Post-Crescent · 4 days ago
FDA Mulling Giredestrant Data in Early-Stage Breast Cancer as Roche Details Late-Stage Failure
FDA Mulling Giredestrant Data in Early-Stage Breast Cancer as Roche Details Late-Stage Failure
Precision Medicine Online · 4 days ago
Roche breast cancer drug under FDA priority review (RHHBY)
Roche breast cancer drug under FDA priority review (RHHBY)
Seeking Alpha · 4 days ago
ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer
ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer
Fierce Biotech · 4 days ago
Swiss Stocks Close Flat; Roche Shares Down
Swiss Stocks Close Flat; Roche Shares Down
marketscreener.com · 5 days ago
Roche Holding (RHHBY) Upgraded to Buy: Here's What You Should Know
Roche Holding (RHHBY) Upgraded to Buy: Here's What You Should Know
Yahoo Finance · 5 days ago
FDA Grants Priority Review to Roche's Early-Stage Breast Cancer NDA
FDA Grants Priority Review to Roche's Early-Stage Breast Cancer NDA
Yahoo Finance · 5 days ago
ASCO26: 'Blunting' effect of CDK4/6 inhibitor may have downed Roche's persevERA study of oral SERD
ASCO26: 'Blunting' effect of CDK4/6 inhibitor may have downed Roche's persevERA study of oral SERD
FirstWord Pharma · 5 days ago
#ASCO26: Roche details narrow failure of breast cancer pill trial
#ASCO26: Roche details narrow failure of breast cancer pill trial
Endpoints News · 5 days ago
FDA Accepts NDA for Roche’s Giredestrant in Early-Stage Breast Cancer
FDA Accepts NDA for Roche’s Giredestrant in Early-Stage Breast Cancer
The Clinical Trial Vanguard · 5 days ago
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
Yahoo Finance · 5 days ago
Jeff Roche
Jeff Roche
Bradley University Athletics · 5 days ago
Vanquishing the Giro-Tour Double: Stephen Roche Scrutinizes Vingegaard’s Chances
Vanquishing the Giro-Tour Double: Stephen Roche Scrutinizes Vingegaard’s Chances
Outside Magazine · 6 days ago
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do
Proactive financial news · 6 days ago